Greenlight Capital’s Filana Therapeutics FLNA Stock Holding History

Greenlight Capital’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-40,620	Closed	-$1.77M	–	57
2021 Q4	$1.77M	Buy	+40,620	New	+$2.13M	0.1%	43

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Greenlight Capital's FLNA Position: Q1 2022 in Review

Greenlight Capital sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 40,620 shares — an estimated $1.77M sold.

Greenlight Capital first reported a position in FLNA in Q4 2021 and held it in 1 quarter. The position peaked at $1.77M in Q4 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

Greenlight Capital reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
Greenlight Capital sold 40,620 Filana Therapeutics shares in Q1 2022, an estimated $1.77M.
Greenlight Capital first reported a position in Filana Therapeutics in Q4 2021 and held it in 1 quarter.
Greenlight Capital's Filana Therapeutics position peaked at $1.77M in Q4 2021.
163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Greenlight Capital's 13F filing for Q1 2022, filed 16 May 2022.